Mizutani C - Search Results

1

Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.

Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F. Ueda Y, et al. Among authors: mizutani c. Leuk Lymphoma. 2013 Jul;54(7):1450-8. doi: 10.3109/10428194.2012.745074. Epub 2012 Nov 26. Leuk Lymphoma. 2013. PMID: 23110324

2

Risk factors for and prognosis of hemorrhagic cystitis after allogeneic stem cell transplantation: retrospective analysis in a single institution.

Arai Y, Maeda T, Sugiura H, Matsui H, Jo T, Ueda T, Okada K, Kawata T, Onishi T, Mizutani C, Ueda Y. Arai Y, et al. Among authors: mizutani c. Hematology. 2012 Jul;17(4):207-14. doi: 10.1179/1607845412Y.0000000010. Hematology. 2012. PMID: 22944099 Free article.

3

Sustained activation of MEK1-ERK1/2 pathway in membrane skeleton occurs dependently on cell adhesion in megakaryocytic differentiation.

Mizutani C, Tohyama Y, Miura Y, Hishita T, Nishihara T, Yamamura H, Ichiyama S, Uchiyama T, Tohyama K. Mizutani C, et al. Biochem Biophys Res Commun. 2002 Sep 27;297(3):664-71. doi: 10.1016/s0006-291x(02)02235-0. Biochem Biophys Res Commun. 2002. PMID: 12270146

4

Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.

Nishihara T, Miura Y, Tohyama Y, Mizutani C, Hishita T, Ichiyama S, Uchiyama T, Tohyama K. Nishihara T, et al. Among authors: mizutani c. Int J Hematol. 2003 Oct;78(3):233-40. doi: 10.1007/BF02983800. Int J Hematol. 2003. PMID: 14604282

5

Adhesion via CD43 induces Syk activation and cell proliferation in TF-1 cells.

Miura Y, Mizutani C, Nishihara T, Hishita T, Yanagi S, Tohyama Y, Ichiyama S, Yamamura H, Uchiyama T, Tohyama K. Miura Y, et al. Among authors: mizutani c. Biochem Biophys Res Commun. 2001 Oct 19;288(1):80-6. doi: 10.1006/bbrc.2001.5729. Biochem Biophys Res Commun. 2001. PMID: 11594755

6

Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone).

Naka R, Tada K, Kaneko H, Nagata O, Tashima M, Mizutani C, Imada K. Naka R, et al. Among authors: mizutani c. Leuk Lymphoma. 2022 Jun;63(6):1508-1511. doi: 10.1080/10428194.2022.2032040. Epub 2022 Feb 2. Leuk Lymphoma. 2022. PMID: 35105261 No abstract available.

7

Successful treatment with paclitaxel of advanced AIDS-associated Kaposi's sarcoma.

Kobayashi M, Takaori-Kondo A, Shindo K, Mizutani C, Ishikawa T, Uchiyama T. Kobayashi M, et al. Among authors: mizutani c. Intern Med. 2002 Dec;41(12):1209-12. doi: 10.2169/internalmedicine.41.1209. Intern Med. 2002. PMID: 12521218 Free article.

8

Refractory immune thrombocytopenic purpura associated with IgM monoclonal gammopathy of undetermined significance: Successful treatment with tirabrutinib plus conventional therapies.

Naka R, Kaneko H, Nagata O, Tada K, Tashima M, Mizutani C, Imada K. Naka R, et al. Among authors: mizutani c. EJHaem. 2022 Mar 17;3(2):513-516. doi: 10.1002/jha2.423. eCollection 2022 May. EJHaem. 2022. PMID: 35846034 Free PMC article.

9

[Rapidly progressive autoimmune pancytopenia successfully treated with steroids].

Mitani S, Okubo Y, Nishi K, Takahashi S, Tada K, Hatanaka K, Kaneko H, Ukyo N, Mizutani C, Imada K. Mitani S, et al. Among authors: mizutani c. Rinsho Ketsueki. 2016;57(11):2324-2328. doi: 10.11406/rinketsu.57.2324. Rinsho Ketsueki. 2016. PMID: 27941280 Japanese.

10

Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.

Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, Mizutani C, Ukyo N, Hirata H, Tsudo M. Konishi Y, et al. Among authors: mizutani c. Tohoku J Exp Med. 2015 Aug;236(4):289-95. doi: 10.1620/tjem.236.289. Tohoku J Exp Med. 2015. PMID: 26250536 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters